Literature DB >> 1543229

Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome.

J S Lopez, M D de Smet, H Masur, B U Mueller, P A Pizzo, R B Nussenblatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1543229     DOI： 10.1016/s0002-9394(14)71588-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  4 in total

1.  Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.

Authors:  S K Moshkani; A Dalimi
Journal:  Vet Res Commun       Date:  2000-04       Impact factor: 2.459

Review 2.  Ophthalmic complications of HIV/AIDS.

Authors:  F G Ah-Fat; M Batterbury
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

3.  In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.

Authors:  S Romand; M Pudney; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

Review 4.  Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.